Joseph McLaughlin, MD
Medical Oncology · Manchester, CTNPI 1013178466
Payments from drug & device makers
Across 260 payments — averaging $869.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$192K
- Regeneron$20K
- Bristol Myers Squibb$12K
- Pfizer$157
- Johnson & Johnson$142
- Novartis$133
- plus $1K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 124 | $192,205 |
| Regeneron | 17 | $19,791 |
| Bristol Myers Squibb | 10 | $12,476 |
| Pfizer | 16 | $157 |
| Johnson & Johnson(2 entities) | 10 | $142 |
| Novartis | 9 | $133 |
| Merck | 9 | $122 |
| Genentech USA, Inc. | 8 | $116 |
| Amgen | 6 | $107 |
| AstraZeneca(2 entities) | 4 | $78 |
| Incyte Corporation | 4 | $60 |
| Tesaro, Inc. | 2 | $53 |
| Bayer | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| GSK | 1 | $33 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $30 |
| Gilead | 2 | $30 |
| Exelixis Inc. | 2 | $29 |
| AbbVie | 2 | $29 |
| Astellas Pharma US Inc | 2 | $29 |
| Lilly USA, LLC | 2 | $29 |
| Puma Biotechnology, Inc. | 2 | $27 |
| Seagen Inc. | 2 | $26 |
| Eisai Inc. | 1 | $22 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Dova Pharmaceuticals | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Fortovia Therapeutics, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Array Biopharma Inc | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
| EMD Serono, Inc. | 1 | $11 |
| Cornerstone Specialty Network LLC | 6 | $0 |
How this compares
$225,965 in reported general payments places this provider in the 50th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Manchester
- Lajos PusztaiNew Haven$23.5M
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.